First description of agonist and antagonist IP-10 in urine of patients with active TB

Petrone, Linda; Bondet, Vincent; Vanini, Valentina; Cuzzi, Gilda; Palmieri, Fabrizio; Palucci, Ivana; Delogu, Giovanni; Ciccosanti, Fabiola; Fimia, Gian María; Blauenfeldt, Thomas; Rühwald, Morten; Duffy, Darragh; Goletti, Delia

doi:10.1016/j.ijid.2018.09.001

Cited by 18 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, IP-10 could monitor anti-TB treatment responses and improve TB diagnosis with HIV 28 . A new form (agonist/antagonist) of IP-10 could be detected in TB patients, and it may help IP-10 in TB diagnosis 29 .…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis

Qiu

Tang

Zou

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Tuberculin skin test and interferon-gamma release assay are not good at differentiating active tuberculosis from latent tuberculosis. Interferon-gamma-induced protein 10 (IP-10) has been widely used to detect tuberculosis infection. However, its values of discriminating active and latent tuberculosis is unknown. To estimate the diagnostic potential of IP-10 for differentiating active tuberculosis from latent tuberculosis, we searched PubMed, Web of Science, Embase, the Cochrane Library, CNKI, Wanfang, VIP and CBM databases. Eleven studies, accounting for 706 participants (853 samples), were included. We used a bivariate diagnostic random-effects model to conduct the primary data. The overall pooled sensitivity, specificity, negative likelihood rate, positive likelihood rate, diagnostic odds ratio and area under the summary receiver operating characteristic curve were 0.72 (95% CI: 0.68–0.76), 0.83 (95% CI: 0.79–0.87), 0.32 (95% CI: 0.22–0.46), 4.63 (95% CI: 2.79–7.69), 17.86 (95% CI: 2.89–38.49) and 0.8638, respectively. This study shows that IP-10 is a potential biomarker for differentiating active tuberculosis from latent tuberculosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis

Qiu

Tang

Zou

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The detection of CXCL10 in urine using ELISA (Quanterix) has a sensitivity of 78% and a specificity of 94%. 22 The detection of the CXCL10 gene in serum has a sensitivity of 87.5% and a specificity of 78.9%. 21 Another study reveals that detection of CXCL10 in serum showed positive results in 87.5% of active pulmonary TB patients, 45.5% of latent TB, and 9.5% in control variables.…”

Section: Discussionmentioning

confidence: 99%

“…The study from Petrone et al in 2019. 22 was conducted using ELISA (Quanterix) to measure CXCL10 in urine, while this research was using PCR. Studies by Nonghanphithak et al in 2017.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis Based on Detection of CXCL10 in Urine as Biomarker for The Determining Diagnosis of Active Lung Tuberculosis

Mertaniasih

Ananda

Soedarsono

et al. 2021

IJTID

View full text Add to dashboard Cite

Tuberculosis diagnosis is an important component in decreasing TB incidence and prevalence. Because of the difficulty to collect sputum in some cases, urine specimens are used as it is easier to garner. One of the biomarkers in urine that can be used to diagnose pulmonary TB is IP-10, which can be represented by the CXCL10 gene. The study aims to determine the accuracy of diagnosis based on detection of the CXCL10 gene in urine as a biomarker for the patients with suspected pulmonary TB in Dr. Soetomo Hospital in Surabaya from November 2019 until March 2020. Thus, this is an observative laboratory research with a cross-sectional study. CXCL10 gene was examined using PCR for 36 urine samples, and then, the data, together with the medical records of clinical manifestations of pulmonary TB, GeneXpert MTB /RIF, blood count, and thorax radiograph, were processed using IBM SPSS Statistics 26. The results of the GeneXpert MTB/RIF and thorax radiograph criteria show positive results of pulmonary TB, which were 44.4% and 69.4% respectively. CXCL10 gene was not found in all urine of healthy people (negative), while 2.8% (1/36 samples) positive CXCL10 gene was found in a patient with positive GeneXpert, also with negative clinical manifestations and urine culture. In this study, the accuracy of diagnosis based on detection of the CXCL10 gene in urine for diagnosis of active pulmonary TB was 2.8%. Future research is needed to improve the methods, among them are bigger size of urine samples and clearer medical history of patients.

show abstract

“…Increased levels of IP-10 are found in blood, plasma or urine in infections such as HIV 35,36 , hepatitis C 37–40 , bacteremia 41,42 and TB 43–50 . It has recently been demonstrated that IP-10 secretion during TB disease originates from infected macrophages and multinucleated giant cells located in the granulomas, and early inactivation of the secreted chemokine by antagonist form of IP-10 which binds to CXCR3 but does not induce signalling, may also play a role in the pathogenesis of TB 51,52 . Several studies show that IP-10 declines during efficient treatment of many diseases including TB 25,38,42,53,54 .…”

Section: Discussionmentioning

confidence: 99%

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting

Hoel

Jørstad

Marijani³

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

Treatment efficacy is difficult to evaluate in extrapulmonary tuberculosis (EPTB) patients. Interferon-γ inducible protein (IP-)10 has been suggested as a biomarker for response to treatment. We have investigated if IP-10 from dried plasma spots (DPS) or dried blood spots (DBS) can be used in treatment monitoring of EPTB patients in a low-resource setting of Zanzibar. IP-10 levels in plasma, DPS and DBS samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, were quantified by an enzyme-linked immunosorbent assay. There was a high positive correlation between IP-10 measured in plasma and DPS and DBS, respectively. We found a significant decline in IP-10 levels from baseline to end of treatment in plasma, DPS and DBS, both in EPTB and PTB patients. The declines were observed already after 2 months in HIV negative patients. In conclusion, the DPS/DBS IP-10 assay allows for easy and manageable monitoring in low-resource settings and our findings suggest that IP-10 may serve as a biomarker for treatment efficacy in EPTB patients, albeit further studies in cohorts of patients with treatment failure and relapse are needed.

show abstract

First description of agonist and antagonist IP-10 in urine of patients with active TB

Abstract: We showed for the first time that agonist/antagonist IP-10 forms are measurable in urine. IP-10 levels associate with TB and pneumonia disease, suggesting their association with acute inflammation. Further studies are needed to assess their role to monitor TB treatment efficacy.

Cited by 18 publications

References 32 publications

Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis

Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis

Diagnosis Based on Detection of CXCL10 in Urine as Biomarker for The Determining Diagnosis of Active Lung Tuberculosis

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting

Contact Info

Product

Resources

About